Summan The retinoblastoma gene (Rb gene) is a tumour-suppressor gene and its product (pRB) is known to act as a negative regulator of the cell cycle. Although lack of pRB expression resulting from gene alterations is considered to be responsible for the genesis of several human malignancies. increased expression of pRB has been demonstrated in a majon'ty of colorectal cancer cases. In the present study. we investigated the expression of pRB as well as that of its related kinases, cdk2 and cdc2, in colorectal cancer, since these kinases have been reported to phosphorylate and inactivate pRB. Western blot analysis revealed that colorectal cancer expressed higher levels of cdk2 and cdc2 than did normal mucosa and that the ratio of the hyperphosphorylated form of pRB was higher in colorectal cancer. Furthermore, immunohistochemical studies showed that cdk2/cdc2 was expressed exclusively in the cancer cells positive for pRB. These results suggest that an increase in the expression of cdk2 cdc2 in colorectal cancer may have prevented pRB from braking the cell cycle through phosphorylation.
The Rb gene is the prototype for tumour-suppressor genes whose biallelic inactivation is responsible for the development of hereditary or sporadic retinoblastomas (Cavenee et al., 1983; Murphree and Benedict. 1984) . Loss of or structural changes within the Rb gene have subsequently been demonstrated in several other human malignancies, including osteosarcomas (Fnrend et al.. 1986 ) and carcinomas of the lung (Harbour et al.. 1988) , breast (Lee et al., 1988) and bladder (Horowitz et al.. 1989) .
In contrast. colorectal cancer has reportedly shown infrequent inactivation of this gene (Vogelstein et al., 1989; Lothe et al., 1992) . and Southern blot analysis has demonstrated Rb gene amplification in approximately 30% of colorectal cancers (Gope et al.. 1990; Meling et al., 1991; Lothe et al.. 1992) . Northern blot and Western blot analyses have revealed elevated expression of the Rb gene in more than half of colorectal cancer cases (Gope et al., 1990; Gope and Gope. 1992; Lothe et al., 1992) .
The Rb gene encodes a nuclear protein of 110 kDa that has multiple phosphorylation sites within the molecule (Lees et al., 1991) . The phosphorylation of pRB is considered to be mediated by several kinases, so-called cdks (cyclin-dependent kinases; Meyerson et al., 1992) , which are activated at specific points of the cell cycle. In normal cells, the underphosphorylated form of pRB is found in the Go and GI phases of the cell cycle, while hyperphosphorylated pRB is present in the S and G2 M phases ).
The underphosphorylated but not the hyperphosphorylated form of pRB is known to be a target of various oncogenic virus proteins such as SV40 large T, adenovirus EIA and human papillomavirus E7 (Whyte et al., 1988; Dyson et al.. 1989: Ludlow et al., 1989) .
Furthermore, it has been demonstrated that the underphosphorylated form of pRB can form a complex with E2F and inhibit its transcriptional activity (Hiebert et al.. 1992) . These data indicate that underphosphorylated pRB is an active form which exhibits a growth-suppressive activity (Chen et al., 1989; Mihara et al., 1989) (Akiyama et al., 1992; Kitagawa et al., 1992) and allows the cells to enter the S phase, while another kinase, cdc2, participates in pRB phosphorylation at G2/M (Lees et al., 1991; Lin et al., 1991) . In the present study, we investigated the expression of cdk2/cdc2 in conjunction with that of pRB in colorectal cancer. Analysis of the expression of these pRBrelated kinases is expected to afford an insight into the significance of Rb gene overexpression in colorectal cancer.
Material and metbods
Antibodies Anti-cdk21cdc2 monoclonal antibody SF6 (Yasui et al., 1993) and anti-cdc2 specific monoclonal antibody 2A10 (Kitagawa et al., 1992) were obtained from Medical and Biological Laboratories (Nagoya, Japan). Both anitbodies were raised against a synthetic peptide including the PSTAIRE motif (Meyerson et al., 1992) common to both cdk2/cdc2 (amino acid residues 30-57 of human p34"'), so that 5F6 recognises both cdk2 and cdc2. whereas 2A10 reacts exclusively with cdc2. Anti-cdk2 polyclonal antibody (Elledge et al., 1992) was purchased from Upstate Biotechnology (Lake Placid, NY, USA). This polyclonal antibody reacts specifically with an epitope within the C-terminal domain (residues 287-298) of human cdk2. Anti-pRB monoclonal antibody PMG3-245 (Jiang et al., 1993; Fukuda et al., 1994) 
Results

Western blotting
Differentiation between cdk2 and cdc2 expresssion by Western blotting was obtained by using specific antibodies for each kinase. Examination of ten matched pairs of normal and cancer tissues revealed that colorectal cancer tissues apparently expressed a higher level of cdk2 and cdc2 than did the corresponding normal mucosa (Figure la and b) . Densitometric analysis of the blotting membranes showed that the amounts of cdk2 and cdc2 expressed in colorectal cancer were respectively, 1.27-4.63 and 1.13 -10.81 times those expressed in normal mucosa (Table I) .
Western blotting for pRB also revealed an increase in the expression of normal-sized pRB in colorectal cancer tissues (Figure 2 ). Densitometry showed that the total amount of pRB with a molecular weight between 110 and 116 kDa in cancer tissue was 0.74-4.06 times that in normal mucosa (Table II) , and the differential quantitation of pRB with a molecular weight over 110 kDa (hyperphosphorylated form : Ludlow et al.. 1989) revealed that the amount of the hyperphosphorylated form of pRB also increased in cancer tissues. The ratio of hyperphosphorylated pRB to total pRB in the cancer tissues was approximately 1-2.5 times that in normal mucosa (Table II) In normal epithelia. cdk2 cdc2 was expressed by a few absorptive cells in the lower part of the glands (Figure 3a) . while cancer tissues contained various numbers of cdk2/cdc2-positive cells (Figure 3b ). The staining showed that cdk2/cdc2 was localised in both the nuclei and the cytoplasm, and the validity of the staining was confirmed by the negative controls immunostained with normal mouse serum or the preabsorbed antibody (Figure 3c) .
Although the 50 cases of colorectal cancer tested always included cells positive for cdk2/cdc2, the incidence of the positive cells was different in each case. We therefore classified the cancers into the following three groups: group a (+ + +), >50% of the cells were positive for cdk2/cdc2; group b (+ +). 10-50% of the cells were positive; and group c (+). <10% of the cells were positive. Of the 50 cases tested, 17 (34%) were classified into group a, 22 (44%) into group b and 11 (22%) into group c. Fifty normal mucosal samples corresponding to each cancer tissue exhibited a low level of expression of cdk2/cdc2, and they were all classified into group c. Thus, the immunohistochemical data showed that cdk2/cdc2 was overexpressed by 39 cases (78%) of the tested colon cancers.
When the relationship between the incidence of cdk.2/cdc2-positive cells and clinicopathological parameters such as tumour size, depth of invasion, metastasis and histological type was investigated, no significant correlation was obtained, but it was found that well-differentiated and moderately differentiated adenocarcinomas, which is the major histological type of colon cancer, exhibited a high incidence of cdk2/cdc2 expression. These findings are summarised in Table III .
We then performed immunohistochemical staining of pRB in the sections adjacent to those stained for cdk2/cdc2. The while an excess amount of cdc2 may assist cell cycle progression through mitosis. To identify cells producing cdk2 and cdc2. we performed an immunohistochemical assay using SF6 monoclonal antibody reactive with both kinases because 2A10 antibody to cdc2 and anti-cdk2 antiserum were not available for immunostaining of the paraffin sections. Localisation of cdk2zcdc2 in normal mucosa indicated that cdk2 cdc2 expression correlated well with the proliferative activity of the cell. The positivity for cdk2 cdc2 dramatically increased in cancer tissues. implying that the number of cells with a potential for replication had increased. The clinicopathological survey of the 50 cases of colorectal cancers showed that the incidence of cdk2 cdc2 overexpression was high in well-differentiated or moderately differentiated adenocarcinomas and was not affected by tumour stage. size. depth of invasion or metastasis. This appears to indicate that the change in cdk2 cdc2 expression is an early event in colorectal carcinogenesis. In fact. in a recent study of focal cancer in adenoma. we found that cdk2 cdc2 was overexpressed even in such an early cancer (data not shown). Immunohistochemical staining for pRB in the serial tissue sections showed that the distribution patterns of cdk2 cdc2-and pRB-positive cells were almost identical in both normal and cancer tissues and it was confirmed that the majority of cells positive for cdk2,cdc2 overexpressed pRB. This finding strongly suggests that cdk2 cdc2 plays a role in the phosphorylation of pRB.
We also found that the hyperphosphorylated form of pRB with a molecular weight over 110 kDa increased in colorectal cancer. and densitometric analysis clearly showed that the majority of cancer tissues had higher percentage of hyperphosphorylated pRB than did normal mucosa. This result is consistent with that reported previously by Gope and Gope (1992) . Although the reason for pRB overexpresion in colorectal cancer still remains to be clarified, a decrease in the percentage of the underphosphorylated form of pRB indicates that pRB overexpressed in cancer cells may not effectively inhibit the cell cycle progression.
This study using Western blotting and immunohistochemistry has demonstrated that overexpression of cdk2 cdc2 in colorectal cancer correlates well with an increase in the percentage of hyperphosphorylated pRB. Concerning the cell cycle regulation. however, further investigation is needed because it has recently been reported that another kinase namely cdk4 (Kato et al.. 1993) . and cellular inhibitors of cdks. including p21 (Xiong et al., 1993) and p16 (Serrano et al., 1993) . participate in the process of pRB phosphorylation.
